Home
Nantkwest

Nantkwest Market Share Analysis for July 2026

immunitybio is dedicated to conquering cancer. we develop therapies that kill disease, not the immune system. learn about our investigational immunotherapy and cell therapy products.

Health > Biotechnology and Pharmaceuticals

Domainnantkwest.com

Year Founded2002

Employees51 - 200

Annual Revenue$25M - $50M

Nantkwest

Nantkwest (including company regionals)

nantkwest.com

See more website traffic and engagement information

Nantkwest Revenue up to July 2026 is 25M - 50M

revenue generated by Nantkwest top domains

Nantkwest top domains revenue over 3 years

Revenue for Nantkwest top domains

nantkwest.com25M - 50M

See more with Sales Intelligence

Total visits to Nantkwest's top domains

Understand Nantkwest market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Nantkwest's top domains

Analyze Nantkwest engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Nantkwest's top domains

See how Nantkwest keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Nantkwest top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Nantkwest

These are the website technologies, by industry, used by Nantkwest top domains

Payment & Currencies (8)

Cart Functionality

Advertising (4)

DoubleClick

Widget (4)

Twemoji

Audio Video Media (2)

YouTube

More Technologies

7

See all

News & Signals from Nantkwest

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNantKwest Inc received financing of $75M in credit facility on Jan 1st '14.Example: In 2014, biotech company NantKwest secured a $75 million credit facility backed by its IP portfolio.

NewsNantKwest Inc launched QUILT on Feb 1st '20.NCT03853317: NantKwest launched a Phase 2 study titled “QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-Shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor” in February 2020.

NewsNantKwest Inc is developing mesenchymal stem cell-based treatment against COVID-19 on Aug 1st '20.In August 2020, NantKwest Inc. collaborated with Generate Life Sciences Co. to develop a mesenchymal stem cell-based treatment against COVID-19.